EGFR and lung adenocarcinoma: Our prevalence of 15.7 % in EGFR-mutated lung adenocarcinomas seems to be among the higher rates in European countries and is closer to what was reported in the Russian study by Moiseyenko, where the prevalence was 19.8 % [27].